Skip to main content

AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · IEX Real-Time Price · USD
5.71
-0.22 (-3.71%)
At close: Dec 29, 2023, 4:00 PM
5.88
+0.17 (2.98%)
After-hours: Dec 29, 2023, 7:44 PM EST

AbCellera Biologics Revenue

AbCellera Biologics had revenue of $50.39M in the twelve months ending September 30, 2023, down -91.65% year-over-year. Revenue in the quarter ending September 30, 2023 was $6.60M, a -93.49% decrease year-over-year. In the year 2022, AbCellera Biologics had annual revenue of $485.42M with 29.38% growth.

Revenue (ttm)
$50.39M
Revenue Growth
-91.65%
P/S Ratio
32.88
Revenue / Employee
$79,987
Employees
630
Market Cap
1.66B USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2022485.42M110.22M
29.38%
Dec 31, 2021375.20M142.05M
60.92%
Dec 31, 2020233.16M221.54M
1,907.88%
Dec 31, 201911.61M2.78M
31.49%
Dec 31, 20188.83M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Oscar Health 5.43B
Alignment Healthcare 1.72B
Omnicell 1.19B
Tilray Brands 650.86M
NovoCure 503.98M
Ironwood Pharmaceuticals 432.38M
Maravai LifeSciences Holdings 419.52M
AtriCure 380.73M
Revenue Rankings

ABCL News

More News